The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.

中文翻译：

---

在临床实践中使用自动胰岛素输送技术的共识建议。

全球糖尿病患病率显着上升且不断上升，这继续给糖尿病患者 (PwD)、医疗保健提供者和付款人带来挑战。虽然维持接近正常的血糖水平已被证明可以预防或延缓糖尿病长期并发症的进展，但很大一部分 PwD 没有达到他们的血糖目标。在过去的 6 年中，我们见证了自动化胰岛素输送 (AID) 技术的巨大进步。大量随机对照试验和真实世界研究表明，使用 AID 系统可以安全有效地帮助 PwD 实现其长期血糖目标，同时降低低血糖风险。因此，AID 系统最近已成为糖尿病管理的一个组成部分。然而，一直缺乏在临床环境中使用 AID 系统的建议。这些指导性建议对于 AID 的成功和接受至关重要。所有与 PwD 打交道的临床医生都需要熟悉可用的系统，以消除糖尿病护理质量方面的差异。本报告为有兴趣使用 AID 的临床医生提供了急需的指导，并提供了一份全面的证据清单，列出了付款人在确定 AID 保险范围的资格标准时应考虑的证据。